Recombinant Human Ephrin-A5 Fc Chimera Protein, CF Summary
Details of Functionality |
Measured by its ability to compete with Biotinylated Recombinant Human Ephrin‑A5 Fc Chimera (Catalog # BT374) for binding to immobilized recombinant mouse Eph-A3 Fc Chimera in a functional ELISA assay. Optimal dilutions should be determined by each laboratory for each application. |
Source |
Mouse myeloma cell line, NS0-derived human Ephrin-A5 protein
Human Ephrin-A5 (Gln21-Asn203) Accession # P52803 |
IEGRMD |
Human IgG1 (Pro100-Lys330) |
6-His tag |
N-terminus |
|
|
C-terminus |
|
|
Accession # |
|
N-terminal Sequence |
No results obtained: Gln21 predicted
|
Structure / Form |
Disulfide-linked homodimer |
Protein/Peptide Type |
Recombinant Proteins |
Gene |
EFNA5 |
Purity |
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
Endotoxin Note |
<0.10 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
|
Theoretical MW |
48.6 kDa (monomer). Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
SDS-PAGE |
50-55 kDa, reducing conditions |
Publications |
Read Publications using 374-EA in the following applications:
|
|
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in PBS. |
Purity |
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
Reconstitution Instructions |
Reconstitute at 200 μg/mL in sterile PBS. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human Ephrin-A5 Fc Chimera Protein, CF
Background
Ephrin‑A5, also known as AL‑1, RAGS, and LERK‑7, is an approximately 25 kDa member of the Ephrin‑A family of GPI‑anchored ligands that bind and induce the tyrosine autophosphorylation of Eph receptors. Ephrin‑A ligands are structurally related to the extracellular domains of the transmembrane Ephrin‑B ligands. Eph‑Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression (1, 2). Ephrin‑A5 preferentially interacts with receptors in the EphA family but also with EphB2 (3). Mature human Ephrin‑A5 shares 99.5% aa sequence identity with mouse and rat Ephrin‑A5, respectively (4). Ephrin‑A5 is expressed in multiple tissues during development, particularly in the brain (5, 6). It can exert repulsive or attractive effects on migrating neurons in the developing brain and motor column of the spinal cord (6‑10). Ephrin‑A5 repels migrating axons by inducing growth cone collapse and neurite retraction and by inhibiting the neurotrophic effects of NGF and BDNF (3, 11, 12). It interacts
in cis with EphA3 on retinal axon growth cones which reduces axonal sensitivity to Ephrin‑A5
in trans (13). In the adult, Ephrin‑A5 is expressed on hippocampal neurons and astrocytes and induces the development of hippocampal synapses (9, 14, 15). It supports the proliferation of neural progenitors and the survival of newly differentiated neurons (14). Ephrin‑A5 also functions as a tumor suppressor (16). Its normal function in inhibiting EGFR signaling is compromised by its down‑regulation in glioma (16). Ephrin‑A5 is also expressed by muscle precursor cells and interacts with EphA4 to restrict their migration to the correct locations during forelimb morphogenesis (17).
- Miao, H. and B. Wang (2009) Int. J. Biochem. Cell Biol. 41:762.
- Pasquale, E.B. (2010) Nat. Rev. Cancer 10:165.
- Himanen, J.-P. et al. (2004) Nat. Neurosci. 7:501.
- Winslow, J.W. et al. (1995) Neuron 14:973.
- Deschamps, C. et al. (2010) BMC Neurosci. 11:105.
- Cooper, M.A. et al. (2009) Dev. Neurobiol. 69:36.
- Frisen, J. et al. (1998) Neuron 20:235.
- Zimmer, G. et al. (2008) Eur. J. Neurosci. 28:62.
- Otal, R. et al. (2006) Neuroscience 141:109.
- Eberhart, J. et al. (2004) J. Neurosci. 24:1070.
- Munoz, L.M. et al. (2005) Dev. Biol. 283:397.
- Meier, C. et al. (2011) PLoS ONE 6:e26089.
- Carvalho, R.F. et al. (2006) Nat. Neurosci. 9:322.
- Hara, Y. et al. (2010) Stem Cells 28:974.
- Akaneya, Y. et al. (2010) PLoS ONE 5:e12486.
- Li, J.-J. et al. (2009) Oncogene 28:1759.
- Swartz, M.E. et al. (2001) Development 128:4669.
Customers Who Viewed This Item Also Viewed...
Species: Mu
Applications: BA
Species: Gp, Hu, Mu, Rb, Rt, Sh, Ye
Applications: B/N, ChIP, Flow, GS, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: CyTOF-ready, Flow, ICC, WB
Species: Hu
Applications: Bind
Species: Hu, Rt
Applications: CyTOF-ready, Flow, ICC, WB
Species: Ca, Hu, Mu, Pm, Rt
Applications: IHC, IHC-P, WB
Species: Mu
Applications: IHC, WB
Species: Mu
Applications: IHC, WB
Species: Hu, Pm, Mu, Rt
Applications: ChIP, IP, WB
Species: Hu, Mu, Rt
Applications: IHC, IHC-P, WB
Species: Mu
Applications: IHC, Simple Western, WB
Species: Mu
Applications: Bind
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Species: Hu
Applications: ICC, IHC, Neut, WB
Species: Hu
Applications: ICC, IHC, Simple Western, WB
Species: Mu
Applications: Bind
Species: Hu
Applications: CyTOF-ready, Flow, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, WB
Species: Hu
Applications: Binding Activity
FAQs for Ephrin-A5 (374-EA) (0)
Additional Ephrin-A5 Products
Blogs on Ephrin-A5